Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 208Multiple Endocrine Neoplasia Type 1 130Thyroid Cancer, Papillary 78Pituitary Neoplasms 70Thyroid Neoplasms 59Pheochromocytoma 55Carcinoma, Neuroendocrine 49Neoplasms 48Carcinoid Tumor 48Carcinoma, Medullary 35Adrenocortical Carcinoma 35Adenocarcinoma, Follicular 34Pancreatic Neoplasms 33Thyroid Carcinoma, Anaplastic 30Neoplasm Metastasis 27Carcinoma, Non-Small-Cell Lung 27Insulinoma 26Breast Neoplasms 25Paraganglioma 24Melanoma 23Colorectal Neoplasms 23Colonic Neoplasms 23Carcinoma, Renal Cell 23Adenoma, Islet Cell 23Somatostatinoma 22Adrenal Gland Neoplasms 22Sarcoma 21Carcinoma, Islet Cell 21Prostatic Neoplasms 20Glucagonoma 19

Interventions

pasireotide 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Dumping Syndrome × Endocrine × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡